Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Brufman

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
In Vivo (Athens, Greece)|November 1, 1987
Functional and morphological alterations following isolated rat stomach irradiation. A model for estimation of radiation injuryZ Weshler, M Ligumsky, G Brufman, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 1, 1990
Radiation therapy for locally advanced breast cancer: prognostic factors and complication rateZ Weshler, G Brufman, A Sulkes, et al.
Journal of Chemotherapy (Florence, Italy)|April 1, 1989
Methylprednisolone and chlorpromazine in patients receiving cancer chemotherapy: a prospective non-randomized studyE Gez, G Brufman, B Kaufman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 1, 1985
Combined modality treatment for stage III ovarian carcinomaS Rizel, S Biran, S O Anteby, et al.
Cancer|August 30, 2000
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinomaO Lyass, B Uziely, R Ben-Yosef, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1997
Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study GroupG Brufman, E Colajori, N Ghilezan, et al.
Oncology|January 1, 1987
High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second studyE Gez, E Warner-Efraty, R Ben-Yosef, et al.
American Journal of Clinical Oncology|July 28, 2001
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter studyI G Ron, N Wigler, R Borovik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer, P Piedbois, P Rougier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors, E Lévy, P Piedbois, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
In Vivo (Athens, Greece)|November 1, 1987
Functional and morphological alterations following isolated rat stomach irradiation. A model for estimation of radiation injuryZ Weshler, M Ligumsky, G Brufman, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 1, 1990
Radiation therapy for locally advanced breast cancer: prognostic factors and complication rateZ Weshler, G Brufman, A Sulkes, et al.
Journal of Chemotherapy (Florence, Italy)|April 1, 1989
Methylprednisolone and chlorpromazine in patients receiving cancer chemotherapy: a prospective non-randomized studyE Gez, G Brufman, B Kaufman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 1, 1985
Combined modality treatment for stage III ovarian carcinomaS Rizel, S Biran, S O Anteby, et al.
Cancer|August 30, 2000
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinomaO Lyass, B Uziely, R Ben-Yosef, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1997
Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study GroupG Brufman, E Colajori, N Ghilezan, et al.
Oncology|January 1, 1987
High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second studyE Gez, E Warner-Efraty, R Ben-Yosef, et al.
American Journal of Clinical Oncology|July 28, 2001
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter studyI G Ron, N Wigler, R Borovik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer, P Piedbois, P Rougier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors, E Lévy, P Piedbois, et al.
Pageof 5